Company Overview and News

 
How a dancer survived osteoporosis

2018-10-15 lifestyle.inquirer.net
“Anyone can get osteoporosis, even someone as active as me,” Anna Marie Periquet says. “But it’s preventable.” She has resumed dancing (above).
MRSGI

 
Supermarket operators report mixed results for 1st six months

2018-08-13 bworldonline
SUPERMARKET operators reported mixed results for the first half of 2018, while posting higher same-store sales growth for the period.
PGCMF MRSGI PRGLY PGOLD

 
4 SSS officials cleared of profiteering charge

2018-06-03 business.inquirer.net
Several months after being accused of profiteering at the expense of their stakeholders, four key officials of the Social Security System (SSS) were cleared by the leadership of the state-administered pension fund, saying accusations against them lacked proof.
MRSGI

1
MRSGI income drops 6% in Q1

2018-05-09 bworldonline - 1
METRO RETAIL Stores Group, Inc. (MRSGI) reported its net income fell by 6% to P90.2 million in the first quarter, as sales were affected after a fire hit its supermarket and department store in Cebu last January.
MRSGI

1
Damaged property from Cebu fire drags Metro Retail profit down 6%

2018-05-09 bworldonline - 1
Metro Retail Stores Group, Inc. reported a 6% decline in net profit at P90 million for the first quarter of 2018, a result of a fire that hit Ayala Center Cebu in January which lasted more than two days.
MRSGI

1
Metro Retail Stores profit rises 24% in 2017

2018-04-11 bworldonline - 1
METRO RETAIL Stores Group, Inc. (MRSGI) reported a 23.7% increase in net income in 2017, amid robust sales across all store formats.
MRSGI

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...